AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Puma Biotechnology, Inc.
Video analysis: PBYI
All videosNo video analysis for this stock yet. Request one from our team.
News: PBYI
Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference
LOS ANGELES--(BUSINESS WIRE)--On Sept. 14, 2026, Puma Biotechnology CEO Alan Auerbach will present a corporate overview at H.C. Wainwright's 28th Annual Global Investment Conf.
Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise
NERLYNX gives PBYI an established revenue stream that can support alisertib's development into a potential second oncology franchise. Currently, PBYI already has positive cash flows and a healthy balance sheet, which I believe should give them flexibility as their R&D progresses. Alisertib's biomarker strategy could identify responsive patients, but bear in mind that it's still a speculative asset in Phase 2 trials.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported its inducement awards granted in August 2026, as required under Nasdaq Listing Rule 5635(c)(4).
3,804,736 Shares in Puma Biotechnology, Inc. $PBYI Bought by BlackRock Inc.
BlackRock Inc. bought a new stake in Puma Biotechnology, Inc. (NASDAQ: PBYI) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,804,736 shares of the biopharmaceutical company's stock, valued at approximately $30,856,000. BlackRock Inc. owned 7.47% of
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.
Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript
Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript
Puma Biotechnology Q2 Earnings Call Highlights
Puma Biotechnology NASDAQ: PBYI reported second-quarter 2026 total revenue of $56.5 million, including $53.6 million in net product revenue from NERLYNX and $2.9 million in royalty revenue. The company posted GAAP net income of $8.2 million, or $0.16 per diluted share, compared with a net loss of $3.8 million, or $0.07 per share, in the first quarter.
Similar companies
-
Eledon Pharmaceuticals, Inc.
ELDN
·
NASDAQ
Compare
-
Abeona Therapeutics Inc.
ABEO
·
NASDAQ
Compare
-
Voyager Therapeutics, Inc.
VYGR
·
NASDAQ
Compare
-
Atea Pharmaceuticals, Inc.
AVIR
·
NASDAQ
Compare
-
Arcturus Therapeutics Holdings Inc.
ARCT
·
NASDAQ
Compare
-
Allogene Therapeutics, Inc.
ALLO
·
NASDAQ
Compare